Summary:
In children with moderate-to-severe asthma and type 2 inflammation, dupilumab combined with medium-dose inhaled corticosteroids (ICS) significantly reduced exacerbations and improved lung function and asthma control compared to placebo combined with continued high-dose ICS, though it was associated with minimal adverse events.
| PICO | Description |
|---|---|
| Population | Children (age not specified) with moderate-to-severe asthma and evidence of type 2 inflammation. |
| Intervention | Dupilumab in combination with medium-dose inhaled corticosteroids (ICS). |
| Comparison | Placebo in combination with continued high-dose inhaled corticosteroids (ICS). |
| Outcome | Dupilumab significantly reduced asthma exacerbations, improved lung function, and enhanced asthma control compared to placebo. Minimal adverse events were noted with dupilumab in this study. |
Source: Leonard B Bacharier, et al. “Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.” Read article here.
